Takeda Pharmaceutical Ownership
| TAK Stock | USD 13.62 0.05 0.37% |
Shares in Circulation | First Issued 2008-09-30 | Previous Quarter 1.6 B | Current Value 3.2 B | Avarage Shares Outstanding 1.6 B | Quarterly Volatility 275.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Takeda |
Takeda Stock Ownership Analysis
The company has price-to-book ratio of 0.94. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Takeda Pharmaceutical has Price/Earnings To Growth (PEG) ratio of 0.7. The entity last dividend was issued on the 27th of March 2024. Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan. Takeda Pharmaceutical operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 47347 people. To find out more about Takeda Pharmaceutical Co contact Christophe Weber at 81 3 3278-2111 or learn more at https://www.takeda.com.Besides selling stocks to institutional investors, Takeda Pharmaceutical also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Takeda Pharmaceutical's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Takeda Pharmaceutical's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Takeda Pharmaceutical Quarterly Liabilities And Stockholders Equity |
|
Less than 1% of Takeda Pharmaceutical Co are currently held by insiders. Unlike Takeda Pharmaceutical's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Takeda Pharmaceutical's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Takeda Pharmaceutical's insider trades
Takeda Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Takeda Pharmaceutical is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Takeda Pharmaceutical Co backward and forwards among themselves. Takeda Pharmaceutical's institutional investor refers to the entity that pools money to purchase Takeda Pharmaceutical's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Managed Asset Portfolios, Llc | 2024-09-30 | 1.6 M | Envestnet Asset Management Inc | 2024-09-30 | 1.4 M | Blackrock Inc | 2024-06-30 | 1.4 M | Causeway Capital Management Llc | 2024-09-30 | 1.3 M | Macquarie Group Ltd | 2024-06-30 | 1 M | Wells Fargo & Co | 2024-06-30 | 871.7 K | Bank Of America Corp | 2024-06-30 | 867.1 K | Jane Street Group Llc | 2024-06-30 | 603.8 K | Kayne Anderson Rudnick Investment Management Llc | 2024-06-30 | 585.8 K | Capital Research Global Investors | 2024-09-30 | 13.1 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 10 M |
Takeda Pharmaceutical Outstanding Bonds
Takeda Pharmaceutical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Takeda Pharmaceutical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Takeda bonds can be classified according to their maturity, which is the date when Takeda Pharmaceutical Co has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| TTWO 355 14 APR 25 Corp BondUS874054AF63 | View | |
| TTWO 37 14 APR 27 Corp BondUS874054AG47 | View | |
| TTWO 4 14 APR 32 Corp BondUS874054AH20 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| TAKEDA PHARMACEUTICAL LTD Corp BondUS874060AW64 | View | |
| TAKEDA PHARMACEUTICAL LTD Corp BondUS874060AX48 | View | |
| TAKEDA PHARMACEUTICAL LTD Corp BondUS874060AY21 | View | |
| TAKEDA PHARMACEUTICAL LTD Corp BondUS874060AZ95 | View |
Takeda Pharmaceutical Corporate Filings
6K | 31st of October 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
FWP | 28th of June 2024 A written communication used by offering participants to offer securities to the public or to solicit securities transactions. | ViewVerify |
| 27th of June 2024 Other Reports | ViewVerify | |
| 25th of April 2024 Other Reports | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios, which includes a position in Takeda Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Takeda Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.049 | Dividend Share 192 | Earnings Share 0.59 | Revenue Per Share 1.4 K | Quarterly Revenue Growth 0.127 |
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Takeda Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.